CAMBRIDGE, Mass., March 03, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it will report fourth quarter and full-year 2019 financial results and provide a business update on Thursday, March 12, 2020.
Management will host a webcast at 8:00 a.m. EST on the same day. The audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. The update may also be accessed by dialing 1-800-289-0045 (domestic) or 1-615-622-8086 (international) five minutes prior to the start of the call and providing the passcode 6394385. An archived webcast will be accessible for 90 days after the event.About Rubius TherapeuticsContact:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
[email protected]Media Contact: 
Dan Budwick
1AB
+1 (973) 271-6085
[email protected]
Bay Street News